
Preliminary results confirm that the addition of bone-protecting agents to Radium-233 (Ra-233) treatment can limit fractures in metastatic castration resistant prostate cancer patients
31 May 2019

Surviving cancer: what is the future?
23 Nov 2017

Prostate cancer: the silent man’s disease
17 Nov 2017

9 Nov 2017

EORTC precision medicine studies deliver medical progress: leaving no one behind
21 Apr 2016

Can RA-223 improve on Enzalutamide efficacy in patients with early castration resistant prostate cancer?
9 Dec 2015

Can abiraterone and radiotherapy improve survival for patients with metastatic prostate cancer treated with ADT?
10 Feb 2015

Dr. Cora Sternberg presented the long term results of EORTC trial 30994 at ASCO 2014 in Chicago
4 Jun 2014